Pharmafile Logo

News and Press Releases

SolasCure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers

Recognises the potential of Aurase Wound Gel to improve outcomes for individuals with calciphylaxis ulcers, a rare and life-threatening condition Represents a new indication for Aurase Wound Gel, currently in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: June 16, 2025

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

SolasCure enrols first patient in a next Phase II clinical trial to advance Aurase Wound Gel

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers 17 March 2025 -- Cambridge,...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: March 17, 2025

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

SolasCure Selected for Innovate UK Global Incubator Programme in Houston

Programme delivered in partnership with the Texas Medical Centre Programme will support Aurase Wound Gel for future entry into US market, advancing SolasCure’s mission to transform chronic wound care for...

Category: Biotechnology, Other
Posted: June 3, 2024

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

SolasCure Awarded £405k Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound Care

Funding will be used to further optimise Aurase Wound Gel for future clinical trials SolasCure aims to deliver the first efficacious, cost-effective and pain-free solution for millions of patients suffering...

Category: Biotechnology
Posted: March 20, 2024

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

SolasCure Publishes Phase 2a Clinical Trial Report in Leading Wound Care Journal

Publication in the ‘International Wound Journal’ provides robust validation of the phase 2a trial data that will enable further clinical studies Study demonstrates proof-of-concept and strong safety profile of Aurase...

Category: Biotechnology
Posted: March 4, 2024

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

SolasCure demonstrates proof-of-concept in phase 2a safety trial of Aurase Wound Gel

Phase 2a clinical trial evaluated Aurase Wound Gel in patients with venous leg ulcers Former Smith+Nephew CMO Andy Weymann joins as chairman to support progression of further phase 2 clinical...

Category: Clinical Trials
Posted: December 12, 2023

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH